Homepage
Author:
Biomea Fusion, Inc.
Posted Date:
May 5, 2026
Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions
Biomea Fusion, Inc.
May 5, 2026
Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment
Biomea Fusion, Inc.
April 27, 2026
Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies
Biomea Fusion, Inc.
March 31, 2026
Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights
Biomea Fusion, Inc.
March 24, 2026
Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026
Biomea Fusion, Inc.
March 14, 2026
Biomea Fusion to Participate at Upcoming Investor Conferences
Biomea Fusion, Inc.
February 19, 2026
